Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
Rhea-AI Summary
TG Therapeutics (NASDAQ: TGTX) published a post hoc pooled analysis from Phase 3 ULTIMATE I and II showing BRIUMVI (ublituximab) produced large, statistically significant reductions in relapses and MRI activity versus teriflunomide in people with highly active relapsing MS.
Key results: ARR 0.145 vs 0.496 (70.8% reduction), early and sustained lesion reductions through Week 96, and markedly higher NEDA-3 rates (77.9% vs 16.4% during Weeks 24–96).
Positive
- ARR -70.8% (0.145 vs 0.496) at Week 96 with BRIUMVI versus teriflunomide
- Gd+ T1 lesions reduced 95.6% during Weeks 0–96 (0.038 vs 0.875)
- NEDA-3 77.9% with BRIUMVI versus 16.4% for teriflunomide during Weeks 24–96 (OR 22.068)
Negative
- Analysis is a post hoc pooled subgroup evaluation rather than a prespecified primary endpoint
- Subgroup sample size is modest (168 participants), which may limit generalizability
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: LEGN +6.51%, CRSP +2.53%, PTCT +0.66%, while MRUS -7.08% and RNA -2.88%, indicating this news is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Clinical milestone payment | Neutral | -2.3% | Payment to Precision BioSciences for azer-cel clinical milestone in MS. |
| Feb 26 | Earnings and guidance | Positive | +4.2% | Strong Q4/FY 2025 BRIUMVI revenues and raised 2026 revenue guidance. |
| Feb 23 | Earnings call announcement | Neutral | +3.5% | Scheduled call to discuss Q4 and full-year 2025 results and outlook. |
| Feb 17 | Long-term efficacy data | Positive | +2.0% | Five-year BRIUMVI ULTIMATE I/II extension data showing durable efficacy. |
| Feb 08 | Awareness collaboration | Positive | +2.5% | MS awareness campaign launched with Christina Applegate and new web platform. |
Recent BRIUMVI-focused and corporate updates have generally coincided with modestly positive price reactions, except for an external milestone payment which saw a small decline.
Over the last month, TG Therapeutics has reported strong BRIUMVI-driven financial results, awareness initiatives, and multiple data publications. An 8-K/earnings event on 02/26 highlighted substantial 2025 revenue growth and raised guidance, with shares rising modestly. Additional BRIUMVI long-term efficacy data on 02/17 and an MS awareness collaboration on 02/08 also saw positive reactions. A clinical milestone payment to a partner on 03/02 coincided with a small decline. Today’s Neurology and Therapy publication continues the pattern of reinforcing BRIUMVI’s MS profile.
Regulatory & Risk Context
The company has an effective Form S-3ASR shelf registration dated 2025-08-08, allowing issuance of various securities over a three-year period. As of the provided data, there have been 0 recorded usage events under this shelf.
Market Pulse Summary
This announcement highlights detailed Phase 3 ULTIMATE I/II post hoc data for BRIUMVI in highly active relapsing MS, showing marked reductions in relapse rates, MRI lesions, and higher NEDA-3 rates through 96 weeks. It builds on earlier long-term efficacy publications and strong BRIUMVI-driven financial results. Investors may watch for how these data support physician adoption, label and guideline discussions, and future development steps alongside the company’s ongoing late-stage programs.
Key Terms
gadolinium-enhancing (gd+) t1 lesion medical
neda-3 medical
annualized relapse rate medical
t2 lesions medical
phase 3 medical
post hoc medical
AI-generated analysis. Not financial advice.
NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of data from a post hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating BRIUMVI® (ublituximab-xiiy) in people with highly active relapsing forms of multiple sclerosis (RMS). The article, authored by Hans-Peter Hartung, MD, of Heinrich Heine University Düsseldorf and colleagues, was published in Neurology and Therapy. The analysis evaluated efficacy outcomes in participants with highly active disease at baseline, defined as ≥2 relapses in the year prior and ≥1 gadolinium-enhancing (Gd+) T1 lesion at baseline. Results demonstrated statistically significant reductions in relapse rates and MRI activity, as well as significantly higher rates of no evidence of disease activity (NEDA-3), with BRIUMVI compared to teriflunomide. Additional details from the publication are included below.
Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, “The publication of these data from a post hoc pooled analysis in Neurology and Therapy further reinforces the efficacy of BRIUMVI to treat people with highly active relapsing MS — a population at risk for rapid disease progression and disability accumulation. These results demonstrate robust and rapid reductions in both clinical and radiologic disease activity and support the use of a high-efficacy therapy such as BRIUMVI early in the disease course.”
Hans-Peter Hartung, MD, Professor of Neurology at Heinrich Heine University Düsseldorf and lead author of the publication noted, “In this subgroup of patients with highly active disease at baseline, ublituximab was associated with significant improvements across multiple measures, including relapse rate, MRI lesion burden, and NEDA-3 outcomes. Benefits were observed as early as Week 12 and sustained through 96 weeks. These findings highlight the importance of early, high-efficacy treatment in individuals with more aggressive disease.”
The article can be accessed at the Neurology and Therapy website or at our TG Therapeutics publication page.
Title: Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis
The post hoc pooled analysis included 168 participants with highly active disease at baseline (ublituximab, n=88; teriflunomide, n=80) from the ULTIMATE I and II trials. Participants were followed for 96 weeks. Highly active disease was defined as ≥2 relapses in the year prior to screening and ≥1 Gd+ T1 lesion at baseline.
Key Efficacy Results
- In participants with highly active disease, the unadjusted annualized relapse rate (ARR) at Week 96 was 0.145 for BRIUMVI versus 0.496 for teriflunomide, representing a
70.8% relative reduction (P<0.001). - At Week 12, BRIUMVI reduced the least squares mean number of Gd+ T1 lesions by
83.3% compared with teriflunomide (0.114 vs 0.683; P<0.001). During Weeks 0–96, Gd+ T1 lesions were reduced by95.6% with BRIUMVI versus teriflunomide (0.038 vs 0.875; P<0.001). - At Week 12, BRIUMVI reduced the number of new or enlarging T2 lesions by
57.5% versus teriflunomide (1.754 vs 4.127; P<0.001). During Weeks 0–96, new or enlarging T2 lesions were reduced by91.1% with BRIUMVI compared to teriflunomide (0.568 vs 6.367; P<0.001). - NEDA-3 rates at Week 12 were
29.5% for BRIUMVI versus10.1% for teriflunomide (OR [95% CI], 4.716 [1.847–12.046]; P=0.001). - NEDA-3 rates during Weeks 24–96 (re-baselined) were
77.9% with BRIUMVI versus16.4% with teriflunomide (OR [95% CI], 22.068 [8.975–54.262]; P<0.001), representing a 4.8-fold higher likelihood of achieving NEDA-3 with BRIUMVI.
ABOUT THE ULTIMATE I & II PHASE 3 TRIALS
ULTIMATE I & II are two randomized, double-blind, double-dummy, parallel group, active comparator-controlled clinical trials of identical design, in patients with RMS treated for 96 weeks. Patients were randomized to receive either BRIUMVI, given as an IV infusion of 150 mg administered in four hours, 450 mg two weeks after the first infusion administered in one hour, and 450 mg every 24 weeks administered in one hour, with oral placebo administered daily; or teriflunomide, the active comparator, given orally as a 14 mg daily dose with IV placebo administered on the same schedule as BRIUMVI. Both studies enrolled patients who had experienced at least one relapse in the previous year, two relapses in the previous two years, or had the presence of a T1 gadolinium (Gd)-enhancing lesion in the previous year. Patients were also required to have an Expanded Disability Status Scale (EDSS) score from 0 to 5.5 at baseline. The ULTIMATE I & II trials enrolled a total of 1,094 patients with RMS across 10 countries. These trials were led by Lawrence Steinman, MD, Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics at Stanford University. Additional information on these clinical trials can be found at www.clinicaltrials.gov (NCT03277261; NCT03277248).
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
ABOUT BRIUMVI® (ublituximab-xiiy) 150 mg/6 mL Injection for IV
BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS. BRIUMVI is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion at low doses.
BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in several countries outside of the U.S. for the treatment of adult patients with RMS with active disease defined by clinical or imaging features.
A list of authorized specialty distributors can be found at www.briumvi.com.
IMPORTANT SAFETY INFORMATION
Contraindications: BRIUMVI is contraindicated in patients with:
- Active Hepatitis B Virus infection
- A history of life-threatening infusion reaction to BRIUMVI
WARNINGS AND PRECAUTIONS
Infusion Reactions: BRIUMVI can cause infusion reactions, which can include pyrexia, chills, headache, influenza-like illness, tachycardia, nausea, throat irritation, erythema, and an anaphylactic reaction. In MS clinical trials, the incidence of infusion reactions in BRIUMVI-treated patients who received infusion reaction-limiting premedication prior to each infusion was
Observe treated patients for infusion reactions during the infusion and for at least one hour after the completion of the first two infusions unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion. Inform patients that infusion reactions can occur up to 24 hours after the infusion. Administer the recommended pre-medication to reduce the frequency and severity of infusion reactions. If life-threatening, stop the infusion immediately, permanently discontinue BRIUMVI, and administer appropriate supportive treatment. Less severe infusion reactions may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment.
Infections: Serious, life-threatening or fatal, bacterial and viral infections have been reported in BRIUMVI-treated patients. In MS clinical trials, the overall rate of infections in BRIUMVI-treated patients was
Consider the potential for increased immunosuppressive effects when initiating BRIUMVI after immunosuppressive therapy or initiating an immunosuppressive therapy after BRIUMVI.
Hepatitis B Virus (HBV) Reactivation: HBV reactivation occurred in an MS patient treated with BRIUMVI in clinical trials. Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with anti-CD20 antibodies. Perform HBV screening in all patients before initiation of treatment with BRIUMVI. Do not start treatment with BRIUMVI in patients with active HBV confirmed by positive results for HB surface antigen (HBsAg) and anti-HB tests. For patients who are negative for HBsAg and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult a liver disease expert before starting and during treatment.
Progressive Multifocal Leukoencephalopathy (PML): PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability. JCV infection resulting in PML has been observed in patients treated with anti-CD20 antibodies, including BRIUMVI, and other MS therapies.
If PML is suspected, withhold BRIUMVI and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.
MRI findings may be apparent before clinical signs or symptoms; monitoring for signs consistent with PML may be useful. Further investigate suspicious findings to allow for an early diagnosis of PML, if present. Following discontinuation of another MS medication associated with PML, lower PML-related mortality and morbidity have been reported in patients who were initially asymptomatic at diagnosis compared to patients who had characteristic clinical signs and symptoms at diagnosis.
If PML is confirmed, treatment with BRIUMVI should be discontinued.
Vaccinations: Administer all immunizations according to immunization guidelines: for live or live-attenuated vaccines, at least 4 weeks and, whenever possible, at least 2 weeks prior to initiation of BRIUMVI for non-live vaccines. BRIUMVI may interfere with the effectiveness of non-live vaccines. The safety of immunization with live or live-attenuated vaccines during or following administration of BRIUMVI has not been studied. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion.
Vaccination of Infants Born to Mothers Treated with BRIUMVI During Pregnancy: In infants of mothers exposed to BRIUMVI during pregnancy, assess B-cell counts prior to administration of live or live-attenuated vaccines as measured by CD19+ B-cells. Depletion of B-cells in these infants may increase the risks from live or live-attenuated vaccines. Inactivated or non-live vaccines may be administered prior to B-cell recovery. Assessment of vaccine immune responses, including consultation with a qualified specialist, should be considered to determine whether a protective immune response was mounted.
Fetal Risk: Based on data from animal studies, BRIUMVI may cause fetal harm when administered to a pregnant woman. Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 B-cell depleting antibodies during pregnancy. Advise females of reproductive potential to use effective contraception during BRIUMVI treatment and for 6 months after the last dose.
Reduction in Immunoglobulins: As expected with any B-cell depleting therapy, decreased immunoglobulin levels were observed. Decrease in immunoglobulin M (IgM) was reported in
Liver Injury: Clinically significant liver injury, without findings of viral hepatitis, has been reported in the postmarketing setting in patients treated with anti-CD20 B-cell depleting therapies approved for the treatment of MS, including BRIUMVI. Signs of liver injury, including markedly elevated serum hepatic enzymes with elevated total bilirubin, have occurred from weeks to months after administration.
Patients treated with BRIUMVI found to have an alanine aminotransaminase (ALT) or aspartate aminotransferase (AST) greater than 3x the upper limit of normal (ULN) with serum total bilirubin greater than 2x ULN are potentially at risk for severe drug-induced liver injury.
Obtain liver function tests prior to initiating treatment with BRIUMVI, and monitor for signs and symptoms of any hepatic injury during treatment. Measure serum aminotransferases, alkaline phosphatase, and bilirubin levels promptly in patients who report symptoms that may indicate liver injury, including new or worsening fatigue, anorexia, nausea, vomiting, right upper abdominal discomfort, dark urine, or jaundice. If liver injury is present and an alternative etiology is not identified, discontinue BRIUMVI.
Most Common Adverse Reactions: The most common adverse reactions in RMS trials (incidence of at least
Physicians, pharmacists, or other healthcare professionals with questions about BRIUMVI should visit www.briumvi.com.
ABOUT BRIUMVI PATIENT SUPPORT in the U.S.
BRIUMVI Patient Support is a flexible program designed by TG Therapeutics to support U.S. patients through their treatment journey in a way that works best for them. More information about the BRIUMVI Patient Support program can be accessed at www.briumvipatientsupport.com.
ABOUT MULTIPLE SCLEROSIS
Relapsing multiple sclerosis (RMS) is a chronic demyelinating disease of the central nervous system (CNS) and includes people with relapsing-remitting multiple sclerosis (RRMS) and people with secondary progressive multiple sclerosis (SPMS) who continue to experience relapses. RRMS is the most common form of multiple sclerosis (MS) and is characterized by episodes of new or worsening signs or symptoms (relapses) followed by periods of recovery. It is estimated that nearly 1 million people are living with MS in the United States and approximately
Cautionary Statement
This press release contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. In addition to the risk factors identified from time to time in our reports filed with the U.S. Securities and Exchange Commission (SEC), factors that could cause our actual results to differ materially include the below.
Such forward looking statements include but are not limited to statements regarding expectations for the timing and success of the commercialization and availability of BRIUMVI® (ublituximab-xiiy) for RMS in the United States, or any jurisdictions outside of the United States; anticipated healthcare professional (HCP) and patient acceptance and use of BRIUMVI for the approved indications; expectations of future revenue for BRIUMVI, or TG expenses or profit estimates or targets; .
Additional factors that could cause our actual results to differ materially include the following: the Company’s ability to continue to commercialize BRIUMVI; the risk that trends in prescriptions are not maintained or that prescriptions are not filled; the failure to obtain and maintain payor coverage; the risk that HCP interest in BRIUMVI will not be sustained; the risk that momentum in sales for BRIUMVI will not be sustained during the course of the year; the risk that the commercialization of BRIUMVI does not continue to exceed expectations; the risk that our BRIUMVI revenue targets will not be achieved; the uncertainties generally inherent in research and development; regulatory developments, legislative actions, executive orders, including the imposition of tariffs and policy changes in the U.S. and other jurisdictions; and general political, economic and business conditions. Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our other filings with the SEC.
Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
CONTACT:
Investor Relations:
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
1. MS Prevalence. National Multiple Sclerosis Society website. https://www.nationalmssociety.org/About-the-Society/MS-Prevalence. Accessed October 26, 2020. 2. Multiple Sclerosis International Federation, 2013 via Datamonitor p. 236.
FAQ
What were the Week 96 relapse results for BRIUMVI in the ULTIMATE pooled analysis (TGTX)?
How much did BRIUMVI reduce MRI lesion activity versus teriflunomide in the TGTX report?
What were the NEDA-3 outcomes with BRIUMVI in the published ULTIMATE pooled analysis (TGTX)?
How soon did BRIUMVI show benefits in people with highly active relapsing MS in the TGTX publication?
What was the size and definition of the highly active subgroup in the ULTIMATE pooled analysis (TGTX)?
